Renalytix Share Discussion Threads

[wan] 08/9/2021 09:09

Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study
BMJ 2021; 374 doi: hxxps://doi.org/10.1136/bmj.n2189 (Published 06 September 2021)
Cite this as: BMJ 2021;374:n2189

People who have recovered from covid-19 have a greater risk of kidney disease, even if they only experienced mild to moderate covid-19 symptoms and were not admitted to hospital, shows a study published in the Journal of the American Society of Nephrology.1

Damage to organ systems such as the kidneys is a recognised complication of the post-acute phase for patients who were severely ill during the acute phase of covid-19, but the risks for patients who experienced milder covid-19 is less clear.

Researchers used data collected by the Veterans Health Administration in the US to compare the risks of kidney related conditions in 89 216 people who had recovered from covid-19 for at least 30 days against the risks in 1 637 467 who had not had covid-19.

Their analysis showed that people who had had covid-19 had a higher risk of acute kidney injury (adjusted hazard ratio (aHR)=1.94; 95% confidence interval 1.86 to 2.04) and major adverse kidney events (aHR 1.66; 95% CI 1.58 to 1.74). Major adverse kidney events were considered to be a decline in the estimated glomerular filtration rate (eGFR) of at least 50% since their first positive covid test, end stage kidney disease, or all cause mortality.

The risk of end stage kidney disease alone—that is, having a kidney transplant or receiving outpatient dialysis—was almost threefold higher for those who recovered from covid-19 (aHR 2.96; 95% CI 2.49-3.51). There were 4.65 cases of end stage kidney disease per 1000 person years among people who had had covid-19 compared with 1.43 cases per 1000 person years among the general population.

Declines in eGFR in those who recovered from covid-19 mirrored the severity of disease they had experienced. Compared with people who had not had covid-19, declines in eGFR ranged from -3.26 mL/min/1.73m2/year for those who had had the disease but not been admitted to hospital, to −5.20 mL/min/1.73m2/year for those who had spent time in hospital, and -7.69 mL/min/1.73m2/year for those who were admitted to intensive care.

Ziyad Al-Aly, director of the clinical epidemiology centre at the Veterans Affairs St Louis Health Care System in Missouri, who led the research said, “These results suggest that beyond the acute phase of covid-19 infection, people experience higher risk adverse kidney outcomes. Post-acute care of people with covid-19 should involve attention and care for acute and chronic kidney disease.”

While the findings suggest that acute kidney injury during the acute phase contribute to the increased risk of post-acute kidney outcomes, he added, “It is also evident that the risk was increased in those who did not have an acute kidney injury during the acute phase.”


It will thus be interesting to see what the collaboration between Renalytix and Mount Sinai Health System reveals on their study of COVID-19 patients and their risk of acute and chronic kidney disease. Researchers at Mount Sinai is utilising Renalytix AI’s KidneyIntelX platform to monitor patients’ kidney disease risk as COVID-19 progresses.

[wan] 03/9/2021 07:21

Renalytix's management is scheduled to participate in a fireside chat Friday, September 10 at 2:40 p.m. EDT. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at investors.renalytix.com .

I look forward to that!

Wells Fargo Securities Research conferences are among the most widely attended on Wall Street, and bring together industry leaders, top executives, financial sponsors and investors to explore market and sector trends. Industry executives are given the opportunity to present their company's corporate and investment highlights, and each year we help more than 5,000 institutional investors explore these investment opportunities.

For additional information, contact your Wells Fargo Representative.

Please note: Wells Fargo Securities Research conferences and forums are by invitation only. Wells Fargo will review all registrants to confirm eligibility. Invitations may not be transferred. Dates and locations are subject to change. For more information please contact your Wells Fargo Securities representative.

[rhatton] 02/9/2021 21:56

When is the PDFUA date here?

[sirshagalot] 02/9/2021 15:27

Its getting a bit cold for shorts soon, late September sends a cold wind up ones trouser leg.

[bertiebingo] 02/9/2021 15:19

You may be effectively lending them out. Lending is pretty standard for most share owners, creates an efficient market and liquid market. I have professionally found that borrows become impossible when it's a company with a screwed balance sheet hence needs capital issues.

[toffeeman] 02/9/2021 12:40

I am trying to understand shorting RENX - the site says there are 550,000 shares available to loan - but which investor would be happy to loan them out?

I guess it might explain the recent volatility.

Strange to me though

[wan] 02/9/2021 09:49

Not to mention that in AstraZeneca's most recent Results Presentation (29th July 21), Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) is highlighted/referred to 24 times -

[wan] 02/9/2021 09:19

Given Renalytix collaboration with AstraZeneca to improve outcomes for patients with chronic disease, and with the parties adopting a multi-phase approach to develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease.

And with recent wide approval of AstraZeneca's Forxiga for the treatment of chronic kidney disease in adults with or without type-2 diabetes, the following is worth a read -
The dawn of a new era in chronic kidney disease


And I am still expecting other pharma collaborations to materialise with Renalytix.

[donald pond] 31/8/2021 08:23

Yes, in the end, once the test is launched we can expect revenues to ramp up very quickly indeed as soon as insurers see that every test will save them a big chunk of cash. It doesn't take particularly optimistic assumptions to come to a fair market cap for this company that is multiples of current levels and backed up by high margin, fast growing revenues.

[mr roper] 31/8/2021 08:20

Nice work, mf. After watching Rnlx do +7% on Friday and +11% yesterday pretty clear there is a big gap to fill here.

Seems to be getting on a few more radars Stateside. Would think the last 4 months of the year will be full of news.

[donald pond] 31/8/2021 08:15

Managed to open a SB at 963 this morning, which, given the performance in the US, was a bit of a gift horse

[mr roper] 30/8/2021 20:24

Should be nearer 1100p tomorrow

[homebrewruss] 30/8/2021 20:05

Ooh, glad I bought some more on the dip! Let's hope the UK market follows suit.

[w13ken] 30/8/2021 18:53

Motley Fool tip: "Renalytix (NASDAQ:RNLX) shares are up around 69% since the beginning of the year. Analysts on Wall Street and beyond think it can go a whole lot higher, too. The consensus price target for Renalytix suggests a 30% gain over recent prices.

Shares of Renalytix have been soaring because it looks as if its chronic-kidney-disease test, KidneyIntelX, can rapidly expand into its healthcare niche. The test employs machine learning techniques to predict which chronic-kidney-disease patients are most likely to progress.

Pricy treatment can prevent bad kidneys from getting worse, but not everyone needs costly intervention to keep off a transplant waiting list. Renalytix recently published results of a budget impact analysis that suggests healthcare plan sponsors can save around $220 per chronic-kidney-disease patient per year by monitoring patients with KidneyIntelX instead of just standard kidney failure detection methods.

According to the CDC, around 37 million Americans have chronic kidney disease. With hard data that proves it can lower America's enormous healthcare bills, a large portion of this group could end up receiving KidneyIntelX tests on a regular basis."

[faz] 30/8/2021 18:48

NOt employed to twiddle his thumbs so I think the market are taking it as another signal FDA approval is imminent

[mr roper] 30/8/2021 17:44

Np, wan. He looks like a heavy hitter alright.
$ rnlx likes it. +9% so far

[wan] 30/8/2021 16:20

Thanks for the heads-up Mr Roper, the market in the US appears impressed too -

Renalytix Appoints Daniel J. Levangie to its Board of Directors
August 30, 2021

Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic
NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J. Levangie to the Company’s board of directors. Mr. Levangie is also appointed as a member of the Company’s remuneration committee.

Mr. Levangie is an experienced executive and long-serving board director in the diagnostics and medical devices industry. He is co-founder and manager of ATON Partners, a private investment firm, and president and CEO of CereVasc, LLC, a medical device company. He also has served on the board of directors of Exact Sciences Corporation (NASDAQ: EXAS) since 2010. From 2013 through January 2017, Mr. Levangie served as president of Insulet Drug Delivery Systems and served as a lead director of Insulet Corporation. From 2011 through 2013, Mr. Levangie was chief executive officer of Dune Medical Devices, Inc., and co-founder and managing partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in 2013. Previously, Mr. Levangie held executive management positions with Cytyc Corporation including executive vice president and chief operating officer, chief executive officer and president until the acquisition of Cytyc by Hologic, in 2007. He served on the board of Hologic from 2007 to 2009.

“Dan brings extensive commercial experience to Renalytix as we begin implementing our KidneyIntelX national marketing strategy to over 200,000 primary care physicians treating an estimated 12 million diabetic kidney disease patients insured by the Government Services Administration, Medicare and Medicare Advantage programs,” said James McCullough, CEO, Renalytix. “He has set a standard for broad-scale up of impactful diagnostic products in the oncology and diabetes markets that will be core to the Renalytix strategy.”

“I’m excited to join the Renalytix team as we bring this important innovation to the market. To be involved in the early commercial scale up and execution of the Renalytix national marketing strategy will be a major step forward for the company and for early-stage patients at risk of future kidney failure, where we can have the greatest impact on improving outcomes and reducing costs. We intend to have a significant impact on the course of the disease of these patients,” said Mr. Levangie.

Full release -

[mr roper] 30/8/2021 13:25

Pretty good looking Director appointment.Exact sciences.

[wan] 26/8/2021 08:20

If you apply the savings to the (unfortunate) stats in the US (globally it's huge), it is indeed both startling and shocking, but KidneyIntelx provides some hope -

Diabetes Statistics
Diabetes is increasing at an alarming rate in the United States. According to the CDC’s (Centers for Disease Control) National Diabetes Statistics Report for 2020 cases of diabetes have risen to an estimated 34.2 million. Below is a summary of the latest diabetes statistics included in the CDC’s report.


CKD is common in people with diabetes. Approximately 1 in 3 adults with diabetes has CKD. Both type 1 and type 2 diabetes can cause kidney disease.

[wan] 26/8/2021 07:33

Today's news of the 'peer reviewed' publication of an external chronic kidney disease budget impact analysis projecting 5-year savings of $1.1 billion dollars for a population of 100,000 patients with type 2 diabetes (T2DKD) and chronic kidney, provides encouraging, if not compelling, detailed clinical and cost analysis supporting the adoption of KidneyIntelx.